Ofev (Nintedanib) is a targeted therapy used in the treatment of certain chronic lung diseases, especially Idiopathic Pulmonary Fibrosis (IPF). It helps slow lung function decline and reduce disease progression.
What is Ofev (Nintedanib)?
Ofev belongs to a class of drugs known as Tyrosine Kinase Inhibitors (TKIs). It works by blocking signals involved in the formation of fibrotic tissue inside the lungs.
In pulmonary fibrosis, scar tissue gradually forms in the lungs, affecting breathing and lung function. Ofev helps to:
Slow down fibrotic tissue formation
Reduce the rate of lung function decline
Improve disease control
In simple terms: It helps slow the progression of lung scarring.
Indications
Ofev (Nintedanib) is used in:
Idiopathic Pulmonary Fibrosis (IPF)
Certain chronic fibrotic lung diseases
Pulmonary fibrosis associated with autoimmune diseases
Dosage and Administration
Standard dose: 150 mg twice daily
Taken orally
Preferably taken with food
Should be taken consistently every day
Dose adjustments may be required based on patient tolerance
Common Side Effects
May include:
Diarrhea
Nausea or vomiting
Loss of appetite
Abdominal pain
Elevated liver enzymes
Weight loss
Regular medical monitoring is important during treatment.
Monitoring During Treatment
Patients on Ofev (Nintedanib) require:
Liver function tests
Monitoring of gastrointestinal symptoms
Lung function assessment
Evaluation of treatment response
Availability & How to Access Treatment
Ofev (Nintedanib) is available through Macrocare’s approved partners.
You can now request and access the medication easily through us.
WhatsApp contact for medication requests: Click here
Ofev (Nintedanib)Ofev (Nintedanib) 150 mg is an effective therapy that helps slow the progression of pulmonary fibrosis and improve disease control, especially in IPF and chronic fibrotic lung diseases.
Medical Disclaimer: This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.
